Filing Details

Accession Number:
0001140361-15-016864
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-04-29 17:44:36
Reporting Period:
2015-04-27
Filing Date:
2015-04-29
Accepted Time:
2015-04-29 17:44:36
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1302573 Oncomed Pharmaceuticals Inc OMED Pharmaceutical Preparations (2834) 383572512
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1553354 J. Alicia Hager C/O Oncomed Pharmaceuticals, Inc.
800 Chesapeake Drive
Redwood City CA 94063
Vp & General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-04-27 1,800 $3.42 16,800 No 4 M Direct
Common Stock Disposition 2015-04-27 945 $25.16 15,855 No 4 S Direct
Common Stock Disposition 2015-04-27 855 $26.19 15,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2015-04-27 1,800 $0.00 1,800 $3.42
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
19,252 2018-07-22 No 4 M Direct
Footnotes
  1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 23, 2015.
  2. Includes 15,000 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
  3. This transaction was executed in multiple trades in prices ranging from $24.90 to $25.48, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  4. This transaction was executed in multiple trades in prices ranging from $26.00 to $26.43, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  5. The option is fully vested and exercisable, subject to a limitation of 175,438 shares that can be issued to a single grantee in a 12-month period upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan.